The presentations will cover the journey from initial identification of attractive (series of) drug-like molecules from the screening of the world largest collection of test molecules using Nuevolution's unique Chemetics™ drug discovery platform technology through the optimization and improvement process in this disease relevant and attractive IL-17A program.

Unique first in class opportunity

IL-17A has presented itself as a very challenging disease protein to inhibit (block) with small molecules and therefore represent a unique, first-in-class, high value opportunity for new topical (e.g. cream or gel) or oral (e.g. tablet) treatment effectively inhibiting IL-17A function.

IL-17A is the key cell signalling molecule responsible for driving multiple inflammatory diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis (type of arthritis in the lower back) and is considered a major contributing factor in diseases such as inflammatory bowel disease (inflammation in the intestines) and multiple sclerosis.

Significant potential

Current IL-17A blockade treatment is only offered through use of very expensive injectable antibodies. Our optimization efforts focus on finalizing data for initially a topical use (treatment on the skin) of our IL-17A blockers as well as seeking a potential systemic (tablet-based) formulation with the ambition of achieving a "first-in-class" development program.

The current annual sales for major inflammatory diseases, i.e. psoriasis, psoriatic arthritis and ankylosing spondylitis amount to USD 16 billion. The potential topical and systemic market for an effective IL 17A blocker is currently estimated to potentially reach USD 27 billion (2024) in annual sales (Global Data, 2016).

The first IL-17A program presentation, disclosed at the Oxford Global 5th Drug Discovery Congress 2018, will be accessible for 48 hours (due to publication restrictions) on the Nuevolution webpage from Thursday 11 October 2018 at 21:00 CET, following which the presentation can be made available upon request.

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0987

Email: tf@nuevolution.com

Alex Haahr Gouliaev, CEO

Phone: +45 7020 0987

Email: ahg@nuevolution.com

For more information on the Nuevolution Chemetics™ platform and further details on the IL-17A program please consult the Nuevolution webpage on: https://nuevolution.com/press/library

About Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and develops its programs alone and in collaboration with pharmaceutical and biotechnology companies to seek future benefit for patients in need of novel medical treatment options. Nuevolution's internal programs are focused on therapeutically important diseases targets within severe inflammatory diseases and cancer.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Thursday 11 October 2018 at 21:00 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com